Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
ABSTRACTPsoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatm...
| Príomhchruthaitheoirí: | , , , , , , , , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Taylor & Francis Group
2023-12-01
|
| Sraith: | mAbs |
| Ábhair: | |
| Rochtain ar líne: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2209920 |